In vivo experiments in xenograft models of prostate cancer has also shown that MCM3AP-AS1 silencing considerably reduces tumor volume, and decreases the ratio of Ki67-expressing cells and expression levels of SLC39A10 in lesions [20]. This evidence concerns the gene SLC39A10 and prostate carcinoma.